RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)
  • 5.0 (3)
  • MEDICINE
RhAPPcast

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

  1. 4 DAYS AGO

    How long has it been since the last ACR LN guideline updates and why is this significant?

    In this educational series, Amanda Mixon, PA-C, President of RhAPP, introduces the latest Lupus Nephritis education based on the updated ACR guidelines. Since the last guidelines in 2012, new therapies like belimumab and voclosporin have revolutionized treatment approaches. The shift from traditional high-dose steroid induction to targeted immune pathway therapies aims to preserve kidney function while reducing medication toxicity. The new guidelines emphasize lower-dose glucocorticoid regimens, triple therapy for Class III & IV Lupus Nephritis, and frequent proteinuria monitoring to optimize patient outcomes. Stay updated with FAQs, podcasts, and medication reviews on the RhAPP website and RhAPP ACE 2.0 Mobile App.

    3 min

  2. JAN 28

    Effectiveness of methotrexate and leflunomide as corticoid – sparing drugs in patients with polymyalgia rheumatica

    Danielle Gatti Palumbo, PharmD, presents a Journal Club discussion on a study evaluating the effectiveness of Methotrexate and Leflunomide as steroid-sparing drugs in patients with Polymyalgia Rheumatica (PMR). The study found that Leflunomide was more effective than Methotrexate in achieving steroid withdrawal and remission, with patients on Leflunomide achieving steroid discontinuation more quickly. Despite both treatments showing similar tolerability, Leflunomide demonstrated superior outcomes in terms of remission and faster steroid withdrawal. The study highlights Leflunomide as a promising option for PMR patients, though further research is needed to confirm these findings.

    4 min
  3. RhAPPcast :The Clinical Utility of Guselkumab in Axial PsA

    JAN 22

    RhAPPcast :The Clinical Utility of Guselkumab in Axial PsA

    Host Amanda Mixon, President of RhAPP, is joined by Audrey Gibson, a Physician Assistant and fellow RhAPP member. They explore the clinical utility of guselkumab for treating axial psoriatic arthritis, a topic gaining significant interest in the rheumatology community.Audrey shares insights from key clinical trials and offers practical advice on using IL-23 inhibitors in clinical practice. Whether you’re an experienced practitioner or new to the field, this discussion will enhance your unders...

    21 min
  4. Journal Club Review Video Module

    JAN 15

    Journal Club Review Video Module

    Amber Hudgins, PharmD, CPP, discusses the efficacy and safety of ixekizumab in biologic-naive patients with psoriatic arthritis, comparing it to adalimumab with and without methotrexate. She dives into the results of the SPIRIT-H2H study, highlighting key findings on joint and skin improvements at 52 weeks. Amber explains how ixekizumab delivers consistent efficacy regardless of methotrexate use, offering valuable insights for evidence-based treatment decisions in PsA management

    6 min
  5. FAQ: How do you interpret radiographic progression using modified-vdHS or mTSS

    JAN 8

    FAQ: How do you interpret radiographic progression using modified-vdHS or mTSS

    Join Kyle George as he explains the use of radiographic scoring systems in assessing structural damage and progression in psoriatic arthritis (PsA). In this informative video, Kyle discusses the modified Van der Heijde Sharp score (mVHS) and the modified Total Sharp score (mTSS), both of which utilize radiographic images to document changes in the hands, wrists, and feet.

    2 min
  6. Med. Review Video Module: What is the efficacy of ixekizumab across the GRAPPA & EULAR domains?

    12/16/2024

    Med. Review Video Module: What is the efficacy of ixekizumab across the GRAPPA & EULAR domains?

    Join Jessica Farrell, PharmD, a clinical pharmacist and board member of RhAPP, as she breaks down the efficacy of ixekizumab across the GRAPPA domains. In this video, she covers the impact of ixekizumab on peripheral arthritis, axial disease, enthesitis, dactylitis, skin, and nail psoriasis, based on the latest clinical trial data. Learn how this treatment can significantly improve various symptoms in patients with psoriatic arthritis.

    7 min
  7. Medication Review Video Module: What is the safety profile of guselkumab in PsO and PsA?

    12/11/2024

    Medication Review Video Module: What is the safety profile of guselkumab in PsO and PsA?

    Join Cassie Dolecki, a clinical pharmacy specialist in Rheumatology at Allegheny Health Network in Pittsburgh, Pennsylvania, as she discusses the safety profile of guselkumab in treating psoriatic arthritis and psoriasis. Cassie highlights findings from the DISCOVER-2 trial, a phase three study that assessed the efficacy and safety of guselkumab compared to placebo in biologic-naive patients with active psoriatic disease over two years.

    2 min
  8. FAQ: How does axial PsA differ from AS clinically, genetically, and radiographically

    12/04/2024

    FAQ: How does axial PsA differ from AS clinically, genetically, and radiographically

    Join Kyle George, a physician assistant and member of RhAPP, as he explores the clinical, genetic, and radiographic differences between axial psoriatic arthritis (Axial PsA) and ankylosing spondylitis (AS). In this FAQ session, Kyle provides insights into how these conditions, despite both causing inflammatory spine pain, differ significantly in their presentation and underlying mechanisms.

    3 min
See All (63)

Ratings & Reviews

5
out of 5
3 Ratings

About

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

Information

  • Creator
    Rheumatology Advanced Practice Providers (RhAPP)
  • Years Active
    2023 - 2025
  • Episodes
    63
  • Rating
    Clean
  • Copyright
    © 2025 RhAPPcast
  • Show Website
    RhAPPcast

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada